R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

The continued questions over new Alzheimer’s treatments

Hailed as a breakthrough after many years without new treatments for Alzheimer’s disease, a new generation of therapies for the condition have not been welcomed by payers.

R&D

Finding a balance: Blending traditional and digital clinical...

It seems to be in our nature to think of things as binary: you prefer the beach over the mountains; you like sweet treats rather than salty; this is correct and that is wrong.

R&D

FTC fears bely a larger tension between pharma, governments

Whether its M&A or drug pricing, pharma companies are increasingly clashing with governments over the balance between affordability and innovation.

Digital

Making grey matter less of a grey area: Angelini Ventures’ a...

Dr Fabrizio Calisti and Dr Thomas Thestrup of Angelini Ventures discuss how their unique medical and scientific knowledge help infuse subject matter expertise and patient insights into the

R&D

Innovation and development of generic pharmaceuticals

Generic drugs are incredibly important in the medical field, not only for their effectiveness, but also for their cost-saving potential for both manufacturers and customers.

R&D

A closer look at gene therapy with PTC Therapeutics

In the latest instalment of the pharmaphorum podcast, editor-in-chief Jonah Comstock connects with Kylie O’Keefe to talk about gene therapy in rare diseases.